Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_182e5bcb9e697c8fe00976d852dd48c8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-801 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
1995-06-05^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd10d7a87a2de2adbc774aa342db9aa0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d1dd7ac09ca96d92a73454226d61231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cd4e1a9b16faed389285b8e1e2f807b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0c01464ccb82d92c840ff81fa8525d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c676c5f6ffee3e7ee30747b6aa3624a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b866a6246fefadfe5392c31adf4f6804 |
publicationDate |
1999-10-29^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BG-62386-B1 |
titleOfInvention |
METHOD FOR TREATMENT OF B-CELL LYMPHOMA |
abstract |
The method can be applied for the treatment of B-cellularlymphoma by a therapeutically effective quantity of at least oneimmunological-active hymeral anti-CD20 antibody applied from about0.001 to about 30 mg per kg bodyweight. The antibody is producedfrom the hybridome secreting it and is identified by the AmericalCollection of Culture Types with deposit No. HB 11388. Theantibody is radioactive labelled by radioisotope selected fromyttrium (90), indium (111) and iodine (131). The method alsoincludes a second application of therapeutically-effectivequantity of at least one immunologically active hymeral anti-CD20antibody which is made about 7 days after the first application. Athird additional therapeutical quantity of at least oneimmunologically active hymeral anti-CD20 antibody is applied 14days after the first application. The radioactive-labelled antiCD20 antobody is applied in the second period.13 claims, 14 figures |
priorityDate |
1992-11-13^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |